FGP
CORT icon

Freestone Grove Partners’s Corcept Therapeutics CORT Stock Holding History

Freestone Grove Partners’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$81 Buy
+2
New +$75 ﹤0.01% 909

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Freestone Grove Partners's CORT Position: Q1 2026 in Review

Freestone Grove Partners opened a new position in Corcept Therapeutics (CORT) in Q1 2026: 2 shares worth $81. The stake represents ﹤0.01% of the portfolio and ranks #909 among its holdings.

351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Freestone Grove Partners held 2 shares of Corcept Therapeutics worth $81 as of Q1 2026.
  • Corcept Therapeutics was a new Freestone Grove Partners position in Q1 2026.
  • Corcept Therapeutics made up ﹤0.01% of Freestone Grove Partners's portfolio in Q1 2026, its #909 holding.
  • 351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.